Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
30.73
+1.30 (4.42%)
At close: Mar 9, 2026, 4:00 PM EDT
30.60
-0.13 (-0.42%)
After-hours: Mar 9, 2026, 5:15 PM EDT

Celldex Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Net Income
-258.76-157.86-141.43-112.33-70.51
Upgrade
Depreciation & Amortization
3.383.183.012.93.07
Upgrade
Loss (Gain) From Sale of Assets
0.010.02-0-0.02
Upgrade
Asset Writedown & Restructuring Costs
----3.5
Upgrade
Loss (Gain) From Sale of Investments
-5.86-15.75-6.220.84-3.21
Upgrade
Stock-Based Compensation
36.2234.2423.8915.618.95
Upgrade
Other Operating Activities
----6.86-1.63
Upgrade
Change in Accounts Receivable
-1.321.93-2.28-0.181.57
Upgrade
Change in Accounts Payable
11.0311.639.383.123.65
Upgrade
Change in Other Net Operating Assets
4.34-35.166.36-6.85-6.28
Upgrade
Operating Cash Flow
-210.95-157.78-107.29-103.73-60.91
Upgrade
Capital Expenditures
-2.71-1.92-1.82-1.83-1.25
Upgrade
Sale of Property, Plant & Equipment
---0.070.03
Upgrade
Investment in Securities
211.79-288.21-103.9691.7-214.93
Upgrade
Investing Cash Flow
209.07-290.13-105.7889.94-216.16
Upgrade
Issuance of Common Stock
2.39441.45218.464.08272.37
Upgrade
Financing Cash Flow
2.39441.45218.464.08272.37
Upgrade
Net Cash Flow
0.52-6.465.39-9.71-4.69
Upgrade
Free Cash Flow
-213.66-159.7-109.11-105.56-62.16
Upgrade
Free Cash Flow Margin
-13829.06%-2274.89%-1585.19%-4478.57%-1336.44%
Upgrade
Free Cash Flow Per Share
-3.22-2.48-2.25-2.25-1.45
Upgrade
Levered Free Cash Flow
-125.54-91.67-46.7-58.03-29.71
Upgrade
Unlevered Free Cash Flow
-125.54-91.67-46.7-58.03-29.71
Upgrade
Change in Working Capital
14.06-21.613.46-3.9-1.05
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.